

William B White

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1886410/publications.pdf>

Version: 2024-02-01

204
papers

12,271
citations

38660

50
h-index

27345

106
g-index

206
all docs

206
docs citations

206
times ranked

11704
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2013, 369, 1327-1335. | 13.9 | 2,261 |
| 2 | Clinical Practice Guidelines for the Management of Hypertension in the Community. <i>Journal of Clinical Hypertension</i> , 2014, 16, 14-26. | 1.0 | 768 |
| 3 | Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. <i>Lancet, The</i> , 2015, 385, 2067-2076. | 6.3 | 659 |
| 4 | Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. <i>Hypertension</i> , 2018, 72, e53-e90. | 1.3 | 629 |
| 5 | Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. <i>New England Journal of Medicine</i> , 2018, 378, 1200-1210. | 13.9 | 601 |
| 6 | Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 262-275.e9. | 2.3 | 371 |
| 7 | Effects of the Selective Aldosterone Blocker Eplerenone Versus the Calcium Antagonist Amlodipine in Systolic Hypertension. <i>Hypertension</i> , 2003, 41, 1021-1026. | 1.3 | 273 |
| 8 | Comparison of thromboembolic events in patients treated with Celecoxib, a Cyclooxygenase-2 specific inhibitor, versus Ibuprofen or Diclofenac. <i>American Journal of Cardiology</i> , 2002, 89, 425-430. | 0.7 | 233 |
| 9 | Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2019, 394, 1540-1550. | 6.3 | 231 |
| 10 | Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension. <i>Hypertension</i> , 2011, 57, 413-420. | 1.3 | 192 |
| 11 | Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib ^{***} The investigators had full access to the data and complete control over the design, conduct analysis, interpretation, and description of the study. The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or in writing the report. The views expressed are those of the investigators alone. <i>American Journal of Cardiology</i> , 2003, 92, 411-418. | 0.7 | 181 |
| 12 | Risk of Cardiovascular Events in Patients Receiving Celecoxib: A Meta-Analysis of Randomized Clinical Trials. <i>American Journal of Cardiology</i> , 2007, 99, 91-98. | 0.7 | 173 |
| 13 | Effects of Celecoxib on Ambulatory Blood Pressure in Hypertensive Patients on ACE Inhibitors. <i>Hypertension</i> , 2002, 39, 929-934. | 1.3 | 141 |
| 14 | EXamination of Cardiovascular Outcomes with AlogliptIN versus Standard of Care in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE). <i>American Heart Journal</i> , 2011, 162, 620-626.e1. | 1.2 | 138 |
| 15 | Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. <i>Blood Pressure Monitoring</i> , 2001, 6, 63-72. | 0.4 | 136 |
| 16 | The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood Pressure. <i>Journal of Clinical Hypertension</i> , 2011, 13, 81-88. | 1.0 | 127 |
| 17 | Heart rate and the rate-pressure product as determinants of cardiovascular risk in patients with hypertension*1. <i>American Journal of Hypertension</i> , 1999, 12, 50S-55S. | 1.0 | 117 |
| 18 | The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases. <i>Drug Safety</i> , 2015, 38, 33-54. | 1.4 | 115 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure impact on the early morning period. <i>American Journal of Hypertension</i> , 2004, 17, 347-353. | 1.0 | 113 |
| 20 | Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. <i>American Journal of Cardiology</i> , 2003, 92, 38-42. | 0.7 | 111 |
| 21 | Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus. <i>Hypertension</i> , 2014, 64, 731-737. | 1.3 | 111 |
| 22 | Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. <i>Journal of the American Society of Hypertension</i> , 2008, 2, 462-468. | 2.3 | 110 |
| 23 | Effects of a New Hormone Therapy, Drospirenone and 17- β -Estradiol, in Postmenopausal Women With Hypertension. <i>Hypertension</i> , 2006, 48, 246-253. | 1.3 | 107 |
| 24 | Ambulatory Blood-Pressure Monitoring in Clinical Practice. <i>New England Journal of Medicine</i> , 2003, 348, 2377-2378. | 13.9 | 106 |
| 25 | Long-term reproducibility of ambulatory blood pressure. <i>Journal of Hypertension</i> , 1994, 12, 703-708. | 0.3 | 105 |
| 26 | Average Daily Blood Pressure, Not Office Blood Pressure, Is Associated With Progression of Cerebrovascular Disease and Cognitive Decline in Older People. <i>Circulation</i> , 2011, 124, 2312-2319. | 1.6 | 104 |
| 27 | Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring. <i>Journal of Clinical Hypertension</i> , 2011, 13, 467-472. | 1.0 | 100 |
| 28 | Antihypertensive Effects of Drospirenone With 17- β -Estradiol, a Novel Hormone Treatment in Postmenopausal Women With Stage 1 Hypertension. <i>Circulation</i> , 2005, 112, 1979-1984. | 1.6 | 99 |
| 29 | Cardiovascular Effects of the Cyclooxygenase Inhibitors. <i>Hypertension</i> , 2007, 49, 408-418. | 1.3 | 97 |
| 30 | Cardiovascular Safety in Patients Receiving Roflumilast for the Treatment of COPD. <i>Chest</i> , 2013, 144, 758-765. | 0.4 | 95 |
| 31 | Effects of Intensive Versus Standard Ambulatory Blood Pressure Control on Cerebrovascular Outcomes in Older People (INFINITY). <i>Circulation</i> , 2019, 140, 1626-1635. | 1.6 | 84 |
| 32 | Nocturnal blood pressure measured by home devices. <i>Journal of Hypertension</i> , 2019, 37, 905-916. | 0.3 | 84 |
| 33 | Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2021, 39, 1742-1767. | 0.3 | 82 |
| 34 | When and how to use self (home) and ambulatory blood pressure monitoring. <i>Journal of the American Society of Hypertension</i> , 2010, 4, 56-61. | 2.3 | 72 |
| 35 | Effects of the Cyclooxygenase-2 Specific Inhibitor Valdecoxib Versus Nonsteroidal Antiinflammatory Agents and Placebo on Cardiovascular Thrombotic Events in Patients with Arthritis. <i>American Journal of Therapeutics</i> , 2004, 11, 244-250. | 0.5 | 71 |
| 36 | ASH Position Paper: Home and Ambulatory Blood Pressure Monitoring—When and How to Use Self (Home) and Ambulatory Blood Pressure Monitoring. <i>Journal of Clinical Hypertension</i> , 2008, 10, 850-855. | 1.0 | 70 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Sham-Controlled Randomized Trials of Catheter-Based Renal Denervation in Patients With Hypertension. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1633-1642. | 1.2 | 69 |
| 38 | Early morning hypertension: what does it contribute to overall cardiovascular risk assessment?. <i>Journal of the American Society of Hypertension</i> , 2008, 2, 397-402. | 2.3 | 63 |
| 39 | Importance of Blood Pressure Control Over a 24-Hour Period. <i>Journal of Managed Care Pharmacy</i> , 2007, 13, 34-39. | 2.2 | 61 |
| 40 | Azilsartan Medoxomil Plus Chlorthalidone Reduces Blood Pressure More Effectively Than Olmesartan Plus Hydrochlorothiazide in Stage 2 Systolic Hypertension. <i>Hypertension</i> , 2012, 60, 310-318. | 1.3 | 59 |
| 41 | Improving the utility of the nocturnal hypertension definition by using absolute sleep blood pressure rather than the "dipping" proportion. <i>American Journal of Cardiology</i> , 2003, 92, 1439-1441. | 0.7 | 58 |
| 42 | Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. <i>American Heart Journal</i> , 2006, 151, 176-184. | 1.2 | 58 |
| 43 | A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2515-2531. | 1.8 | 58 |
| 44 | Chronotherapeutics for Cardiovascular Disease. <i>Drugs</i> , 1998, 55, 631-643. | 4.9 | 57 |
| 45 | A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder. <i>American Heart Journal</i> , 2012, 163, 27-32. | 1.2 | 57 |
| 46 | Relevance of blood pressure variation in the circadian onset of cardiovascular events. <i>Journal of Hypertension</i> , 2003, 21, S9-S15. | 0.3 | 55 |
| 47 | Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin) <i>Tj ETQq1 1 0.784314 rg54/Overlaid</i> | 1.4 | 54 |
| 48 | Rapid Buildup of Brain White Matter Hyperintensities Over 4 Years Linked to Ambulatory Blood Pressure, Mobility, Cognition, and Depression in Old Persons. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2013, 68, 1387-1394. | 1.7 | 53 |
| 49 | Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: <sc>T</sc>he <sc>EXAMINE</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 664-671. | 2.2 | 53 |
| 50 | Safety and Tolerability of the Direct Renin Inhibitor Aliskiren: A Pooled Analysis of Clinical Experience in More Than 12,000 Patients With Hypertension. <i>Journal of Clinical Hypertension</i> , 2010, 12, 765-775. | 1.0 | 52 |
| 51 | Effects of combination therapy with captopril and nifedipine in severe or resistant hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 1986, 39, 43-48. | 2.3 | 49 |
| 52 | Smoking-Related Morbidity and Mortality in the Cardiovascular Setting. <i>Preventive Cardiology</i> , 2007, 10, 1-4. | 1.1 | 47 |
| 53 | Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. <i>Diabetes Care</i> , 2016, 39, 1267-1273. | 4.3 | 47 |
| 54 | Effects of the Cyclooxygenase Inhibiting Nitric Oxide Donator Naproxenolol Versus Naproxen on Systemic Blood Pressure in Patients With Osteoarthritis–Conflicts of interest: Dr. White reports receiving research support during the past 12 months from the National Institutes of Health, Bethesda, Maryland; the Catherine and Patrick Donaghue Medical Research Foundation, West Hartford, Connecticut; the American Heart Association, Dallas, Texas; and Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. <i>D. American Journal of Cardiology</i> , 2009, 104, 840-845. | 0.7 | 46 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Utilizing ambulatory blood pressure recordings to evaluate antihypertensive drug therapy. <i>American Journal of Cardiology</i> , 1992, 69, 8-12. | 0.7 | 45 |
| 56 | Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidity. <i>American Heart Journal</i> , 2012, 164, 14-20. | 1.2 | 45 |
| 57 | Detection, evaluation, and treatment of severe and resistant hypertension. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 743-757. | 2.3 | 45 |
| 58 | Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1 and 2 hypertension. <i>Blood Pressure Monitoring</i> , 2010, 15, 205-212. | 0.4 | 44 |
| 59 | History and Justification of a National Blood Pressure Measurement Validated Device Listing. <i>Hypertension</i> , 2019, 73, 258-264. | 1.3 | 43 |
| 60 | Effects of chronic nitrendipine on casual (office) and 24-hour ambulatory blood pressure. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 38, 60-64. | 2.3 | 41 |
| 61 | Methods of blood pressure determination to assess antihypertensive agents: Are casual measurements enough?. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 45, 581-586. | 2.3 | 41 |
| 62 | Blood Pressure-Lowering Efficacy of the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone: A Factorial Study. <i>Journal of Clinical Hypertension</i> , 2012, 14, 284-292. | 1.0 | 41 |
| 63 | Defining the Problem of Treating the Patient with Hypertension and Arthritis Pain. <i>American Journal of Medicine</i> , 2009, 122, S3-S9. | 0.6 | 38 |
| 64 | Intensive versus Standard Ambulatory Blood Pressure Lowering to Prevent Functional Decline in the Elderly (INFINITY). <i>American Heart Journal</i> , 2013, 165, 258-265.e1. | 1.2 | 38 |
| 65 | Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial. <i>Blood Pressure Monitoring</i> , 2005, 10, 157-163. | 0.4 | 37 |
| 66 | Effects of the Angiotensin II Receptor Blockers Telmisartan vs Valsartan in Combination With Hydrochlorothiazide 25 mg Once Daily for the Treatment of Hypertension. <i>Journal of Clinical Hypertension</i> , 2006, 8, 626-633. | 1.0 | 37 |
| 67 | Renal denervation therapy for hypertension: pathways for moving development forward. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 341-350. | 2.3 | 36 |
| 68 | Impact of smoking cessation on ambulatory blood pressure and heart rate in postmenopausal women. <i>American Journal of Hypertension</i> , 2001, 14, 942-949. | 1.0 | 34 |
| 69 | Ambulatory blood pressure monitoring in the 21st century. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1108-1111. | 1.0 | 33 |
| 70 | Alpha-methyldopa disposition in mothers with hypertension and in their breast-fed infants. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 37, 387-390. | 2.3 | 32 |
| 71 | Cardiovascular risk, hypertension, and NSAIDs. <i>Current Rheumatology Reports</i> , 2007, 9, 36-43. | 2.1 | 31 |
| 72 | Relating Cardiovascular Risk to Out-of-Office Blood Pressure and the Importance of Controlling Blood Pressure 24 Hours a Day. <i>American Journal of Medicine</i> , 2008, 121, S2-S7. | 0.6 | 30 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Assessment of drug-induced increases in blood pressure during drug development: Report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , 2013, 165, 477-488. | 1.2 | 30 |
| 74 | Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 200-205. | 1.4 | 30 |
| 75 | Functional reach of older adults: normative reference values based on new and published data. <i>Physiotherapy</i> , 2017, 103, 387-391. | 0.2 | 30 |
| 76 | High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 622 Metabolism, 2018, 20, 654-659. | 2.2 | 30 |
| 77 | Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial. <i>Diabetes Care</i> , 2018, 41, 1510-1515. | 4.3 | 30 |
| 78 | Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. <i>Blood Pressure Monitoring</i> , 2008, 13, 21-27. | 0.4 | 28 |
| 79 | Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 398-405. | 2.2 | 28 |
| 80 | Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e012797. | 1.6 | 28 |
| 81 | Effects of graded-release diltiazem versus ramipril, dosed at bedtime, on early morning blood pressure, heart rate, and the rate-pressure product. <i>American Heart Journal</i> , 2004, 148, 628-634. | 1.2 | 27 |
| 82 | Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1462-1471. | 2.9 | 27 |
| 83 | Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. <i>Journal of Hypertension</i> , 2016, 34, 788-797. | 0.3 | 26 |
| 84 | Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 962-969. | 2.2 | 26 |
| 85 | Update on the drug treatment of hypertension in patients with cardiovascular disease. <i>American Journal of Medicine</i> , 2005, 118, 695-705. | 0.6 | 25 |
| 86 | Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: A report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , 2015, 169, 197-204. | 1.2 | 25 |
| 87 | The effects of the long-acting angiotensin-converting enzyme inhibitor cilazapril on casual, exercise, and ambulatory blood pressure. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 44, 173-178. | 2.3 | 23 |
| 88 | Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension. <i>Blood Pressure Monitoring</i> , 2008, 13, 123-129. | 0.4 | 23 |
| 89 | Safety and Tolerability of the Direct Renin Inhibitor Aliskiren in Combination With Angiotensin Receptor Blockers and Thiazide Diuretics: A Pooled Analysis of Clinical Experience of 12,942 Patients. <i>Journal of Clinical Hypertension</i> , 2011, 13, 506-516. | 1.0 | 23 |
| 90 | Income level and inequality as complement to geographical differences in cardiovascular trials. <i>American Heart Journal</i> , 2019, 218, 66-74. | 1.2 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial. <i>Clinical Research in Cardiology</i> , 2021, 110, 1006-1019. | 1.5 | 23 |
| 92 | Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 755-762. | 2.3 | 22 |
| 93 | Cardiovascular Effects of Incretin-Based Therapies. <i>Annual Review of Medicine</i> , 2016, 67, 245-260. | 5.0 | 22 |
| 94 | Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , 2015, 169, 486-495. | 1.2 | 21 |
| 95 | Effects of the novel norepinephrine prodrug, droxidopa, on ambulatory blood pressure in patients with neurogenic orthostatic hypotension. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 819-826. | 2.3 | 21 |
| 96 | Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. <i>Hypertension</i> , 2016, 68, 606-613. | 1.3 | 21 |
| 97 | Gender and age effects on the ambulatory blood pressure and heart rate responses to antihypertensive therapy. <i>American Journal of Hypertension</i> , 2001, 14, 1239-1247. | 1.0 | 20 |
| 98 | Systolic versus diastolic blood pressure versus pulse pressure. <i>Current Cardiology Reports</i> , 2002, 4, 463-467. | 1.3 | 20 |
| 99 | Clinical trial experience around the globe: Focus on calcium-channel blockers. <i>Clinical Cardiology</i> , 2003, 26, 7-11. | 0.7 | 20 |
| 100 | Improving Blood Pressure Control: Increase the Dose of Diuretic or Switch to a Fixed-Dose Angiotensin Receptor Blocker/Diuretic? The Valsartan Hydrochlorothiazide Diuretic for Initial Control and Titration to Achieve Optimal Therapeutic Effect (Val-DICTATE) Trial. <i>Journal of Clinical Hypertension</i> , 2008, 10, 450-458. | 1.0 | 20 |
| 101 | Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study. <i>American Journal of Nephrology</i> , 2018, 48, 172-180. | 1.4 | 20 |
| 102 | Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1701-1710. | 2.2 | 20 |
| 103 | Transtelephonic Home Blood Pressure to Assess the Monoamine Oxidase-B Inhibitor Rasagiline in Parkinson Disease. <i>Hypertension</i> , 2008, 52, 587-593. | 1.3 | 19 |
| 104 | Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e009114. | 1.6 | 19 |
| 105 | Managing Hypertension with Ambulatory Blood Pressure Monitoring. <i>Current Cardiology Reports</i> , 2015, 17, 2. | 1.3 | 18 |
| 106 | Cardiorenal Safety of OTC Analgesics. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 103-118. | 1.0 | 18 |
| 107 | Chronopharmacology of cardiovascular therapy. <i>Blood Pressure Monitoring</i> , 2002, 7, 199-207. | 0.4 | 17 |
| 108 | Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial. <i>American Journal of Medicine</i> , 2018, 131, 813-819.e5. | 0.6 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome. <i>Journal of the American Society of Hypertension</i> , 2018, 12, 768-778.e1. | 2.3 | 17 |
| 110 | Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. <i>Rheumatology</i> , 2019, 58, 61-69. | 0.9 | 17 |
| 111 | â€œInappropriateâ€•physician habits in prescribing oral nifedipine capsules in hospitalized patients. <i>American Journal of Hypertension</i> , 1996, 9, 1035-1039. | 1.0 | 16 |
| 112 | Effects of Naproxinod on Blood Pressure in Patients With Osteoarthritis. <i>American Journal of Cardiology</i> , 2011, 107, 1338-1345. | 0.7 | 16 |
| 113 | Review of the state of renal nerve ablation for patients with severe and resistant hypertension. <i>Journal of the American Society of Hypertension</i> , 2013, 7, 484-493. | 2.3 | 16 |
| 114 | Gout, Xanthine Oxidase Inhibition, and Cardiovascular Outcomes. <i>Circulation</i> , 2018, 138, 1127-1129. | 1.6 | 16 |
| 115 | Red cell distribution width in patients with diabetes and myocardial infarction: An analysis from the <scp>EXAMINE</scp> trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1580-1587. | 2.2 | 16 |
| 116 | Longitudinal microstructural changes of cerebral white matter and their association with mobility performance in older persons. <i>PLoS ONE</i> , 2018, 13, e0194051. | 1.1 | 16 |
| 117 | Clinical Assessment of Early Morning Blood Pressure in Patients With Hypertension. <i>Preventive Cardiology</i> , 2007, 10, 210-214. | 1.1 | 15 |
| 118 | Cardiovascular Safety of the Î² ₃ -Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1084-1091. | 1.0 | 15 |
| 119 | Cardiovascular risk, hypertension, and NSAIDs. <i>Current Pain and Headache Reports</i> , 2007, 11, 428-435. | 1.3 | 14 |
| 120 | Evaluating Cardiovascular Safety of Novel Therapeutic Agents for the Treatment of Type 2 Diabetes Mellitus. <i>Current Cardiology Reports</i> , 2014, 16, 541. | 1.3 | 14 |
| 121 | Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension. <i>American Journal of Cardiology</i> , 2017, 119, 1111-1115. | 0.7 | 14 |
| 122 | Relationships among clinic, home, and ambulatory blood pressures with small vessel disease of the brain and functional status in older people with hypertension. <i>American Heart Journal</i> , 2018, 205, 21-30. | 1.2 | 14 |
| 123 | Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome. <i>Clinical Research in Cardiology</i> , 2021, 110, 1612-1624. | 1.5 | 14 |
| 124 | Effects of a Novel Oral Testosterone Undecanoate on Ambulatory Blood Pressure in Hypogonadal Men. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 630-637. | 1.0 | 14 |
| 125 | Effects of the oral testosterone undecanoate Kyzatrexâ„¢ on ambulatory blood pressure in hypogonadal men. <i>Journal of Clinical Hypertension</i> , 2021, 23, 1420-1430. | 1.0 | 14 |
| 126 | Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising. <i>American Heart Journal</i> , 2002, 144, 657-665. | 1.2 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension. <i>American Journal of Hypertension</i> , 2003, 16, 739-745. | 1.0 | 13 |
| 128 | Thalamic Fractional Anisotropy Predicts Accrual of Cerebral White Matter Damage in Older Subjects with Small-Vessel Disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 1321-1327. | 2.4 | 13 |
| 129 | Timed mobility: description of measurement, performance, and dimensionality among older adults. <i>Disability and Rehabilitation</i> , 2018, 40, 2011-2014. | 0.9 | 13 |
| 130 | Patiromer and Spironolactone in Resistant Hypertension and Advanced CKD: Analysis of the Randomized AMBER Trial. <i>Kidney360</i> , 2021, 2, 425-434. | 0.9 | 13 |
| 131 | Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease. <i>Postgraduate Medicine</i> , 2023, 135, 224-233. | 0.9 | 13 |
| 132 | Tricenter Assessment of the Efficacy of the ACE Inhibitor, Moexipril, by Ambulatory Blood Pressure Monitoring. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 233-238. | 1.0 | 12 |
| 133 | Is It Possible to Manage Hypertension and Evaluate Therapy Without Ambulatory Blood Pressure Monitoring?. <i>Current Hypertension Reports</i> , 2012, 14, 366-373. | 1.5 | 12 |
| 134 | Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). <i>American Journal of Cardiology</i> , 2019, 123, 382-391. | 0.7 | 12 |
| 135 | Accuracy and analysis of ambulatory blood pressure monitoring data. <i>Clinical Cardiology</i> , 1992, 15, 10-13. | 0.7 | 11 |
| 136 | Treatment of Benign Prostatic Hyperplasia in Hypertensive Men. <i>Journal of Clinical Hypertension</i> , 2005, 7, 212-217. | 1.0 | 11 |
| 137 | Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. <i>Journal of Hypertension</i> , 2017, 35, 761-768. | 0.3 | 11 |
| 138 | Cardiovascular Safety of the Selective μ -Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 309-317. | 1.0 | 10 |
| 139 | Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial. <i>Arthritis and Rheumatology</i> , 2022, 74, 1593-1601. | 2.9 | 10 |
| 140 | Effects of chronic cetamolol therapy on resting, ambulatory, and exercise blood pressure and heart rate. <i>Clinical Pharmacology and Therapeutics</i> , 1986, 39, 664-668. | 2.3 | 9 |
| 141 | The Role of Ambulatory Monitoring of the Blood Pressure for Assessment of Antihypertensive Agents. <i>Journal of Clinical Pharmacology</i> , 1992, 32, 524-528. | 1.0 | 9 |
| 142 | Importance of Aggressive Blood Pressure Lowering When It May Matter Most. <i>American Journal of Cardiology</i> , 2007, 100, S10-S16. | 0.7 | 9 |
| 143 | Effects of the hormone therapy, drospirenone and 17-beta estradiol, on early morning blood pressure in postmenopausal women with hypertension. <i>Journal of the American Society of Hypertension</i> , 2008, 2, 20-27. | 2.3 | 9 |
| 144 | The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure) Tj ETQq0 0 0 rg 13/Overlook 10 Tf 50 | | |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects. <i>Blood Pressure Monitoring</i> , 2018, 23, 153-163. | 0.4 | 9 |
| 146 | Early and Chronic Dipeptidylâ€Peptidaseâ€IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. <i>Journal of the American Heart Association</i> , 2018, 7, . | 1.6 | 9 |
| 147 | Angiotensin-Converting Enzyme Inhibitors in the Treatment of Hypertension: An Update. <i>Journal of Clinical Hypertension</i> , 2007, 9, 876-882. | 1.0 | 8 |
| 148 | Blood and Urine Biomarkers Predicting Worsening Kidney Function in Patients with Type 2 Diabetes Post-Acute Coronary Syndrome: An Analysis from the EXAMINE Trial. <i>American Journal of Nephrology</i> , 2021, 52, 969-976. | 1.4 | 8 |
| 149 | Ejaculatory Failure and Urinary Dysfunction Secondary to Labetalol. <i>Journal of Urology</i> , 1988, 139, 371-372. | 0.2 | 7 |
| 150 | Clinical utility of ambulatory blood pressure: perspectives for national insurance coverage. <i>Blood Pressure Monitoring</i> , 2002, 7, 27-31. | 0.4 | 7 |
| 151 | Ambulatory Blood Pressure Monitoring as an Investigative Tool for Characterizing Resistant Hypertension and Its Rational Treatment. <i>Journal of Clinical Hypertension</i> , 2007, 9, 25-30. | 1.0 | 7 |
| 152 | Rationale for Establishing a Mechanism to Increase Reimbursement to Hypertension Specialists. <i>Journal of Clinical Hypertension</i> , 2013, 15, 397-403. | 1.0 | 7 |
| 153 | Exposure to Racial Discrimination and Ambulatory Blood Pressure in Women with Type 2 Diabetes. <i>Stress and Health</i> , 2016, 32, 337-345. | 1.4 | 7 |
| 154 | Cardiovascular safety of therapies for type 2 diabetes. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 13-25. | 1.0 | 7 |
| 155 | Effects of a Stateâ€and Useâ€Dependent Nav1.7 Channel Blocker on Ambulatory Blood Pressure: A Randomized, Controlled Crossover Study. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 90-97. | 1.0 | 7 |
| 156 | Severe, accelerated postpartum hypertension associated with hyperthyroxinaemia. Case report. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1986, 93, 1297-1299. | 1.1 | 6 |
| 157 | Effects of metoprolol succinate extended release vs. amlodipine besylate on the blood pressure, heart rate, and the rate-pressure product in patients with hypertension. <i>Journal of the American Society of Hypertension</i> , 2008, 2, 378-384. | 2.3 | 6 |
| 158 | Evaluation of the Migraine Treatment Sumatriptan/Naproxen Sodium on Blood Pressure Following Long-Term Administration. <i>Journal of Clinical Hypertension</i> , 2011, 13, 910-916. | 1.0 | 6 |
| 159 | Diagnostic evaluation. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 939-941. | 2.3 | 6 |
| 160 | â€Translationalâ€medicine: transforming SPRINT findings into clinical practice. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 382-386. | 2.3 | 6 |
| 161 | Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. <i>American Heart Journal</i> , 2016, 175, 18-27. | 1.2 | 6 |
| 162 | Evaluation of the angiotensin <sc>ll</sc> receptor blocker azilsartan medoxomil in Africanâ€American patients with hypertension. <i>Journal of Clinical Hypertension</i> , 2017, 19, 695-701. | 1.0 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 163 | Impact of the Norepinephrine Prodrug Droxidopa on the QTc Interval in Healthy Individuals. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 332-340. | 0.8 | 6 |
| 164 | Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. <i>American Journal of Cardiology</i> , 2018, 122, 1496-1505. | 0.7 | 6 |
| 165 | Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial. <i>Blood Pressure Monitoring</i> , 2022, 27, 128-134. | 0.4 | 6 |
| 166 | Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome. <i>Clinical Cardiology</i> , 2018, 41, 1022-1027. | 0.7 | 5 |
| 167 | Patiromer to Enable Spironolactone in Patients with Resistant Hypertension and CKD (AMBER). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1407-1409. | 2.2 | 5 |
| 168 | Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial. <i>Cardiovascular Diabetology</i> , 2021, 20, 187. | 2.7 | 5 |
| 169 | Pharmacologic Agents in the Management of Hypertension—Nisoldipine Coat-Core. <i>Journal of Clinical Hypertension</i> , 2007, 9, 259-266. | 1.0 | 4 |
| 170 | A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension. <i>Journal of Hypertension</i> , 2018, 36, 947-956. | 0.3 | 4 |
| 171 | Cardiovascular Safety of Febuxostat. <i>New England Journal of Medicine</i> , 2018, 379, 1582-1584. | 13.9 | 4 |
| 172 | Cardiovascular Effects of the Selective Cyclooxygenase-2 Inhibitors. <i>Sub-Cellular Biochemistry</i> , 2007, 42, 145-158. | 1.0 | 4 |
| 173 | Rofecoxib, but not celecoxib or naproxen, increases mean 24-hour systolic blood pressure: results of a randomized double blind controlled trial in treated hypertensive patients with osteoarthritis (OA) and type 2 diabetes mellitus. <i>American Journal of Hypertension</i> , 2003, 16, A11. | 1.0 | 3 |
| 174 | Thomas G. Pickering. <i>Hypertension</i> , 2009, 54, 917-918. | 1.3 | 3 |
| 175 | The Potential Role of Nitric Oxide in Cardiovascular Safety When Treating Patients with Osteoarthritis and Hypertension: A Moderated Panel Discussion. <i>American Journal of Medicine</i> , 2009, 122, S23-S25. | 0.6 | 3 |
| 176 | Leadership Message: American Society of Hypertension-Designated Centers of Excellence: A New Initiative. <i>Journal of Clinical Hypertension</i> , 2011, 13, 391-392. | 1.0 | 3 |
| 177 | Response to Letter to the Editor by Blankfield regarding "Assessment of drug-induced increases in blood pressure during drug development: Report from the Cardiac Safety Research Consortium." <i>American Heart Journal</i> , 2013, 166, e11. | 1.2 | 3 |
| 178 | Ambulatory Blood Pressure Monitoring: Technique and Application in the Study of Cardiac Dysfunction and Congestive Heart Failure. <i>Congestive Heart Failure</i> , 2001, 7, 319-324. | 2.0 | 2 |
| 179 | Severe and refractory hypertension in a young woman. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 506-509. | 2.3 | 2 |
| 180 | Clinical Precision in the Management of Hypertension. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1611-1613. | 1.2 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Methodological and Regulatory Considerations for Updated Guidance on the Pressor Effects of Drugs. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 1473-1476. | 0.8 | 2 |
| 182 | Comparative effects of telmisartan in the treatment of hypertension. <i>Journal of Clinical Hypertension</i> , 2002, 4, 20-5. | 1.0 | 2 |
| 183 | Hypertension management: differing points of view: ambulatory blood pressure monitoring for every hypertensive patient: it's about time!: the argument against. <i>Journal of Clinical Hypertension</i> , 2004, 6, 710-3; quiz 714. | 1.0 | 2 |
| 184 | Cardiovascular risk and ambulatory blood pressure. <i>Current Hypertension Reports</i> , 1999, 1, 509-511. | 1.5 | 1 |
| 185 | Home Blood Pressure Monitoring as an Intervention to Control Hypertension. <i>Archives of Internal Medicine</i> , 2011, 171, 1181. | 4.3 | 1 |
| 186 | EXAMINE: targeting risk and treatment in diabetes – Authors' reply. <i>Lancet, The</i> , 2015, 386, 1445. | 6.3 | 1 |
| 187 | Severe and resistant hypertension in an older woman with claudication. <i>Journal of the American Society of Hypertension</i> , 2017, 11, 475-479. | 2.3 | 1 |
| 188 | Ambulatory Blood Pressure Monitoring in Older Persons. , 2016, , 209-225. | | 1 |
| 189 | Acute pain in the tip of the index finger. <i>American Journal of Medicine</i> , 2005, 118, 1223-1224. | 0.6 | 0 |
| 190 | Response to a New Hormone Therapy With Drospirenone and NO Production in Postmenopausal Women. <i>Hypertension</i> , 2006, 48, . | 1.3 | 0 |
| 191 | Matching the circadian rhythms of hypertension with pharmacotherapy. <i>Clinical Cardiology</i> , 2003, 26, 10-15. | 0.7 | 0 |
| 192 | Blood Pressure Monitoring enters its 14th year. <i>Blood Pressure Monitoring</i> , 2009, 14, 1. | 0.4 | 0 |
| 193 | The present and future of the American Society of Hypertension: 2012. <i>Journal of the American Society of Hypertension</i> , 2012, 6, 237-239. | 2.3 | 0 |
| 194 | The Present and Future of the American Society of Hypertension – 2012. <i>Journal of Clinical Hypertension</i> , 2012, 14, 401-403. | 1.0 | 0 |
| 195 | Cardiovascular Safety of Roflumilast: Response. <i>Chest</i> , 2013, 144, 1082-1083. | 0.4 | 0 |
| 196 | The 20th year of Blood Pressure Monitoring. <i>Blood Pressure Monitoring</i> , 2015, 20, 1. | 0.4 | 0 |
| 197 | A New Era of Renal Denervation Trials for Patients With Hypertension?. <i>American Journal of Kidney Diseases</i> , 2018, 71, 615-618. | 2.1 | 0 |
| 198 | Management of Hypertension in Athletes. , 2018, , 49-67. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | The Silver Anniversary of Blood Pressure Monitoring. Blood Pressure Monitoring, 2020, 25, 1-1. | 0.4 | 0 |
| 200 | Individual patient risk assessment and cost-benefit analysis of patiromer in AMBER Authors' reply. Lancet, The, 2020, 396, 311-312. | 6.3 | 0 |
| 201 | SO033PATIROMER TO ENABLE SPIRONOLACTONE IN PATIENTS WITH RESISTANT HYPERTENSION AND CHRONIC KIDNEY DISEASE (AMBER): PRESPECIFIED RESULTS BY BASELINE SERUM POTASSIUM. Nephrology Dialysis Transplantation, 2020, 35, . | 0.4 | 0 |
| 202 | Response to Letter Regarding Article, "Effects of Intensive Versus Standard Ambulatory Blood Pressure Control on Cerebrovascular Outcomes in Older People (INFINITY)" Circulation, 2020, 141, e652-e653. | 1.6 | 0 |
| 203 | Spirolactone for resistant hypertension in advanced chronic kidney disease"red, amber or green?. Nephrology Dialysis Transplantation, 2020, 35, 1288-1290. | 0.4 | 0 |
| 204 | Module 1: Historical review of evidence-based treatment of hypertension. Journal of Family Practice, 2012, 61, S5-14; quiz S27. | 0.2 | 0 |